MedTrace Logo

Efficacy and Safety of TACE on Downstaging Hepatocellular Carcinoma Beyond UCSF Criteria;

NCT04738188 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 226

Last updated 2021-02-04

No results posted yet for this study

Summary

This is a multicenter, randomized, parallel controlled study to determine the efficacy and safety of transcatheter arterial chemoembolization (TACE) on downstaging hepatocellular carcinoma beyond University of California, San Francisco (UCSF) criteria.

Conditions

Interventions

PROCEDURE

DEB-TACE

Drug-eluting beads transcatheter arterial chemoembolization

PROCEDURE

cTACE

Transcatheter arterial chemoembolization

DEVICE

Drug-eluting Beads

Drug-eluting beads

DRUG

Epirubicin

Chemotherapy drug for intra-arterial infusion

Sponsors & Collaborators

  • Beijing Tsinghua Chang Gung Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-18
Primary Completion
2022-11-30
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04738188 on ClinicalTrials.gov